Literature DB >> 15497692

Tryptophan residues play an important role in the extraordinarily high affinity binding interaction of UCN-01 to human alpha-1-acid glycoprotein.

Masaaki Katsuki1, Victor Tuan Giam Chuang, Koji Nishi, Ayaka Suenaga, Masaki Otagiri.   

Abstract

PURPOSE: To investigate the factors that contribute to the exceptionally high affinity binding of UCN-01 to human alpha1-acid glycoprotein (hAGP).
METHODS: Interactions between UCN-01, UCN-02, and staurosporine with native and chemically modified hAGPs were examined using ultracentrifugation and spectroscopic analysis.
RESULTS: The binding affinity of staurosporine, as well as UCN-02, to hAGP was lower than that of UCN-01 by 20- and 100-fold respectively. The percentage of UCN-01 that binds to hAGP was low at acidic pH but increased with increasing pH, reaching a maximum at pH 7.4. The binding of UCN-01 to desialylated hAGP was comparable to that of hAGP. No significant difference was found for the binding of UCN-01 to F1*S and A variants of hAGP. Chemical modification of the His, Lys, Trp, and Tyr residues caused a decrease in percentage of bound UCN-01. Trp-modified hAGP showed the largest decrease in binding. Tryptophanyl fluorescence quenching results indicate that Trp residues play a prominent role in the binding of UCN-01 to hAGP.
CONCLUSIONS: A substituent at position C-7 of UCN-01 appeared to influence the binding specificity of the drug, and Trp residues in hAGP play a prominent role in the high affinity binding of UCN-01 to hAGP.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15497692     DOI: 10.1023/b:pham.0000041461.93787.6b

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  39 in total

Review 1.  Drug binding to human alpha-1-acid glycoprotein in health and disease.

Authors:  J M Kremer; J Wilting; L H Janssen
Journal:  Pharmacol Rev       Date:  1988-03       Impact factor: 25.468

2.  Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.

Authors:  E A Sausville; S G Arbuck; R Messmann; D Headlee; K S Bauer; R M Lush; A Murgo; W D Figg; T Lahusen; S Jaken; X Jing ; M Roberge; E Fuse; T Kuwabara; A M Senderowicz
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

3.  Tetranitromethane. A reagent for the nitration of tyrosyl residues in proteins.

Authors:  M Sokolovsky; J F Riordan; B L Vallee
Journal:  Biochemistry       Date:  1966-11       Impact factor: 3.162

4.  Steroid-protein interactions. XXXIV. Chemical modification of alpha1-acid glycoprotein for characterization of the progesterone binding site.

Authors:  T Kute; U Westphal
Journal:  Biochim Biophys Acta       Date:  1976-01-20

5.  Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition.

Authors:  David Komander; Gursant S Kular; Jennifer Bain; Matthew Elliott; Dario R Alessi; Daan M F Van Aalten
Journal:  Biochem J       Date:  2003-10-15       Impact factor: 3.857

6.  pH-dependence of warfarin binding to alpha 1-acid glycoprotein (orosomucoid).

Authors:  S Urien; F Brée; B Testa; J P Tillement
Journal:  Biochem J       Date:  1993-02-01       Impact factor: 3.857

7.  Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.

Authors:  E Fuse; H Tanii; N Kurata; H Kobayashi; Y Shimada; T Tamura; Y Sasaki; Y Tanigawara; R D Lush; D Headlee; W D Figg; S G Arbuck; A M Senderowicz; E A Sausville; S Akinaga; T Kuwabara; S Kobayashi
Journal:  Cancer Res       Date:  1998-08-01       Impact factor: 12.701

8.  Ligand specificity of the genetic variants of human alpha1-acid glycoprotein: generation of a three-dimensional quantitative structure-activity relationship model for drug binding to the A variant.

Authors:  F Hervé; G Caron; J C Duché; P Gaillard; N Abd Rahman; A Tsantili-Kakoulidou; P A Carrupt; P d'Athis; J P Tillement; B Testa
Journal:  Mol Pharmacol       Date:  1998-07       Impact factor: 4.436

9.  Orosomucoid system: 17 additional orosomucoid variants and proposal for a new nomenclature.

Authors:  I Yuasa; S Weidinger; K Umetsu; K Suenaga; G Ishimoto; B C Eap; J C Duche; P Baumann
Journal:  Vox Sang       Date:  1993       Impact factor: 2.144

10.  UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities.

Authors:  I Takahashi; Y Saitoh; M Yoshida; H Sano; H Nakano; M Morimoto; T Tamaoki
Journal:  J Antibiot (Tokyo)       Date:  1989-04       Impact factor: 2.649

View more
  1 in total

1.  Structural insights into differences in drug-binding selectivity between two forms of human alpha1-acid glycoprotein genetic variants, the A and F1*S forms.

Authors:  Koji Nishi; Tomomi Ono; Teruya Nakamura; Naoko Fukunaga; Miyoko Izumi; Hiroshi Watanabe; Ayaka Suenaga; Toru Maruyama; Yuriko Yamagata; Stephen Curry; Masaki Otagiri
Journal:  J Biol Chem       Date:  2011-02-24       Impact factor: 5.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.